Results 301 to 310 of about 382,034 (365)
Multiscale analysis and optimal glioma therapeutic candidate discovery using the CANDO platform. [PDF]
J CheminformXu S +6 more
europepmc +1 more source
Long-read transcriptomic profiling of a glioma cell line following m6A regulator perturbations. [PDF]
Biochem Biophys RepLee H +11 more
europepmc +1 more source
Erratum to: Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor. [PDF]
Neuro Oncoleuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Biomaterials, 2018
Currently, glioma treatment is limited by two main factors: timely detection at onset or relapse and restriction of drugs by the blood-brain barrier (BBB) from entering the brain and influencing tumor growth.
Yanli An, Yinan Ding, Chen He
exaly +2 more sources
Currently, glioma treatment is limited by two main factors: timely detection at onset or relapse and restriction of drugs by the blood-brain barrier (BBB) from entering the brain and influencing tumor growth.
Yanli An, Yinan Ding, Chen He
exaly +2 more sources
Nature Reviews Disease Primers
Gliomas are primary brain tumours that are thought to develop from neural stem or progenitor cells that carry tumour-initiating genetic alterations. Based on microscopic appearance and molecular characteristics, they are classified according to the WHO classification of central nervous system (CNS) tumours and graded into CNS WHO grades 1-4 from a low ...
Michael Weller +6 more
semanticscholar +4 more sources
Gliomas are primary brain tumours that are thought to develop from neural stem or progenitor cells that carry tumour-initiating genetic alterations. Based on microscopic appearance and molecular characteristics, they are classified according to the WHO classification of central nervous system (CNS) tumours and graded into CNS WHO grades 1-4 from a low ...
Michael Weller +6 more
semanticscholar +4 more sources
2023
Benign glioma broadly refers to a heterogeneous group of slow-growing glial tumors with low proliferative rates and a more indolent clinical course. These tumors may also be described as "low-grade" glioma (LGG) and are classified as WHO grade I or II lesions according to the Classification of Tumors of the Central Nervous System (CNS) (Louis et al. in
Peter B, Wu +3 more
openaire +2 more sources
Benign glioma broadly refers to a heterogeneous group of slow-growing glial tumors with low proliferative rates and a more indolent clinical course. These tumors may also be described as "low-grade" glioma (LGG) and are classified as WHO grade I or II lesions according to the Classification of Tumors of the Central Nervous System (CNS) (Louis et al. in
Peter B, Wu +3 more
openaire +2 more sources
The Lancet Oncology, 2021
BACKGROUND Effective treatments are needed to improve outcomes for high-grade glioma and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in adult patients with recurrent or progressive BRAFV600E mutation-positive ...
P. Wen +25 more
semanticscholar +1 more source
BACKGROUND Effective treatments are needed to improve outcomes for high-grade glioma and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in adult patients with recurrent or progressive BRAFV600E mutation-positive ...
P. Wen +25 more
semanticscholar +1 more source